Mode
Text Size
Log in / Sign up
N/A N=20 Randomized Treatment

NewGait: A Low-Cost Rehabilitation System to Improve Post-Stroke Gait (Biomechanical Adaptations)

Stroke

Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Gait Speed — 0.90; 0.92; 0.88; 0.87 meters per second — p=0.894

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
NewGait (Other); Control wearable limb orthotic device (Other)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
University of Michigan
Primary completion
Dec 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Gait Speed
0.90; 0.92; 0.88; 0.87; 0.91; 0.92 0.894
PRIMARY
Ankle Muscle Activation
75.29; 72.98; 62.41; 66.77; 67.77; 75.46 >0.299
SECONDARY
Changes in Paretic Leg Propulsive Force
8.22; 8.03; 11.92; 11.36; 8.70; 9.00 0.469

Summary

An affordable and easy to use gait-assistive device for stroke survivors to use at home is yet to be developed. This study is intended to modify the current design of the NewGait device to specifically work for stroke survivors based on feedback from patients and clinicians. Consequently, conducting a short-term biomechanical gait study is planned to determine the usability and functionality of the NewGait device compared to other comparative devices.

Eligibility Criteria

Inclusion Criteria

  • Unilateral cortical or subcortical stroke
  • Chronic stroke (≥ 6 months) At least 6 months following their first unilateral stroke
  • Able to walk independently with/without assistive devices for 5-10 mins (~150m)
  • No significant cognitive deficits as determined by the Mini Mental State Examination (MMSE) score (score≥ 22)

Exclusion Criteria

  • Cerebellar stroke
  • Traumatic or vascular brain injury
  • History of unstable heart condition, uncontrolled diabetes/hypertension
  • History of a recent lower-extremity trauma or fracture
  • History of a recent significant orthopedic or neurological conditions that could limit walking ability (e.g., multiple sclerosis, total knee replacement)
  • Documented history of significant spatial neglect
  • ankle joint contractures or significant spasticity in the lower limbs
  • History of a recent Botulinum Toxin (Botox) injection to the lower-extremity muscles (≤ 3 months)
  • Pregnant or actively planning to become pregnant (self-reported)- Inability to communicate or unable to consent
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06269367). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search